Technology areas: Biotechnology & Pharmaceuticals • Communications • Semiconductors, Circuits & Optics
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Akoya Biosciences, Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 4 distinct examiners and 4 distinct art units, indicating that the current prosecution workload is spread across separate examination assignments rather than concentrated in one technical grouping.
NEFF, MICHAEL R is the busiest examiner, with 1 pending matter. Because that figure represents only part of the portfolio, counsel should coordinate docket review across the assigned examiners and art units. The distributed assignment pattern makes consistent claim strategy, disclosure support, and response timing important across the biotechnology matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEFF, MICHAEL R | 1 | 87.6% | +14.5% |
| CAPUTO, LISA M | 1 | 42.4% | +5.4% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.8% |
| RILEY, JEZIA | 1 | 83.0% | +7.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17743799 | Amplification of RNA Detection Signals in Biological Samples | RILEY, JEZIA | 24d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19026723 | PROCESSING AND IMAGING TISSUE SAMPLES | NEFF, MICHAEL R | — |
| 18717652 | SURFACE SENSING IN AUTOMATED SAMPLE ANALYSIS | CAPUTO, LISA M | — |
| 17961630 | Detection of Co-Occurring Receptor-Coding Nucleic Acid Segments | KAPUSHOC, STEPHEN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19026723 | PROCESSING AND IMAGING TISSUE SAMPLES | NEFF, MICHAEL R | — |
| 17961630 | Detection of Co-Occurring Receptor-Coding Nucleic Acid Segments | KAPUSHOC, STEPHEN THOMAS | — |
| Art Unit | Apps |
|---|---|
| 2631 | 1 |
| 2874 | 1 |
| 1600 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19026723 | PROCESSING AND IMAGING TISSUE SAMPLES | NEFF, MICHAEL R | 2631 | §101 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18717652 | SURFACE SENSING IN AUTOMATED SAMPLE ANALYSIS | CAPUTO, LISA M | 2874 | §102§103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 17961630 | Detection of Co-Occurring Receptor-Coding Nucleic Acid Segments | KAPUSHOC, STEPHEN THOMAS | 1600 | §103§112Other | Final Rejection | — | Pending | Oct 07, 2022 |
| 17743799 | Amplification of RNA Detection Signals in Biological Samples | RILEY, JEZIA | 1681 | §103 | Final Rejection | 24d overdue | Pending | May 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAkoya Biosciences, Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Michael R Neff has the most, with 1 of Akoya Biosciences, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
